Your browser doesn't support javascript.
loading
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas, Jesus; Martínez-Urbistondo, Diego; Velázquez Kennedy, Kyra; Villares, Paula; Barquin, Arántzazu; Dominguez, Andrea; Rodriguez-Moreno, Juan Francisco; Caro, Elena; Suarez Del Villar, Rafael; Nistal-Villan, Estanislao; Yagüe, Monica; Ortiz, Maria; Barba, Maria; Ruiz-Llorente, Sergio; Quiralte, Miguel; Zanin, Massimiliano; Rodríguez, Cristina; Navarro, Paloma; Berraondo, Pedro; Madurga, Rodrigo.
Afiliación
  • Garcia-Donas J; Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CE
  • Martínez-Urbistondo D; Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain.
  • Velázquez Kennedy K; Hematology Department, Universitario Hospital Ramon y Cajal, Madrid, Spain.
  • Villares P; Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain.
  • Barquin A; Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CE
  • Dominguez A; Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain.
  • Rodriguez-Moreno JF; Gynecological, Genitourinary and Skin Cancer Unit HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo CEU, CE
  • Caro E; Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain.
  • Suarez Del Villar R; Internal Medicine Service Hospital HM Sanchinarro, Madrid, Spain.
  • Nistal-Villan E; Microbiology Section, Dpto. CC, Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, Madrid, Spain.
  • Yagüe M; Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, Madrid, Spain.
  • Ortiz M; Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universitie
  • Barba M; Clinical Trials Pharmacy, Clara Campal Comprehensive Cancer Center, Hospital Universitario de Sanchinarro, Madrid, Spain.
  • Ruiz-Llorente S; Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universitie
  • Quiralte M; Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universitie
  • Zanin M; Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universitie
  • Rodríguez C; Instituto de Física Interdisciplinar y Sistemas Complejos IFISC (CSIC-UIB), Palma de Mallorca, Spain.
  • Navarro P; Grupo de Cáncer Endocirno, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
  • Berraondo P; Laboratory of Innovation in Oncology HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Department of Basic Medical Sciences, Facultad de Medicina, Hospital Universitario HM Sanchinarro, HM Hospitales, Institute of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU, CEU Universitie
  • Madurga R; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Front Immunol ; 14: 1156603, 2023.
Article en En | MEDLINE | ID: mdl-37143685
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Deterioro Clínico / COVID-19 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Respiratoria / Deterioro Clínico / COVID-19 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article Pais de publicación: Suiza